Form 4: ALAM JOHN J reports acquisition/exercise transactions in CRVO

Rhea-AI Filing Summary

ALAM JOHN J reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 75,000 shares. Following the reported transactions, holdings were 75,000 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALAM JOHN J

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.8	02/11/2026		A		75,000		(1)	02/11/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CervoMed (CRVO) report for John J. Alam?

CervoMed reported a stock option grant to CEO John J. Alam. He received 75,000 options to buy common stock, awarded on February 11, 2026, as part of his compensation package, with specific multi-year vesting terms tied to continued service.

How many CervoMed (CRVO) stock options were granted to the CEO?

John J. Alam was granted 75,000 stock options. Each option gives him the right to purchase one share of CervoMed common stock, subject to vesting over three years in monthly installments, which encourages long-term alignment with the company’s performance and shareholder interests.

What is the exercise price of the new CervoMed (CRVO) stock options?

The granted stock options have an exercise price of $4.80 per share. This means John J. Alam can purchase CervoMed common stock at $4.80 when options vest and are exercised, potentially benefiting if the market price exceeds this fixed exercise level.

When do John J. Alam’s CervoMed (CRVO) options begin vesting?

The options begin vesting on February 28, 2026. Vesting then continues in 36 equal or near-equal monthly installments on the last day of each month, spreading the award over three years and linking value realization to his ongoing role with the company.

Over what period will the CervoMed (CRVO) CEO’s stock options vest?

The 75,000 options will vest over a 36-month period. Vesting occurs in monthly installments on the last calendar day of each month, starting February 28, 2026, creating a gradual, service-based schedule that supports long-term retention and incentive alignment for the CEO.

How many CervoMed (CRVO) derivative securities does the CEO own after this grant?

After the transaction, John J. Alam beneficially owns 75,000 derivative securities. These consist of the newly granted stock options, held directly, each tied to one share of CervoMed common stock, subject to the detailed monthly vesting schedule disclosed in the filing.